Erbitux Phase IV Trials To Study EGFR-Negative Populations
Executive Summary
Bristol-Myers Squibb and ImClone's post-approval commitments include an examination of the efficacy of Erbitux in patients with EGFR-negative colorectal cancer
You may also be interested in...
Erbitux Launch Benefits From EGFR Screening; 75%-80% Of Patients Positive
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
Erbitux Launch Benefits From EGFR Screening; 75%-80% Of Patients Positive
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May
AstraZeneca is launching the lung cancer agent Iressa at a 25% discount to Novartis' chronic myelogenous leukemia therapy Gleevec